Final Height in Patients With CAH
NCT04293133 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2020-03-03
Summary
Congenital adrenal hyperplasia (CAH) is the most common inherited disorder in the adrenal gland in children. Growth is usually affected in CAH patients either due to the disease itself or treatment consequences.
Conditions
- Congenital Adrenal Hyperplasia
Sponsors & Collaborators
-
Ain Shams University
lead OTHER
Principal Investigators
-
Rana Ahmed · Ain Shams University
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-03-11
- Primary Completion
- 2020-08-11
- Completion
- 2020-09-11
More Related Trials
-
Gonadal Changes In Congenital Adrenal Hyperplasia Patients
NCT04903587 ·Status: UNKNOWN
-
Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
NCT05162950 ·Status: UNKNOWN
-
Questionnaire Study to Assess the Outcomes of the Management of Congenital Adrenal Hyperplasia Individuals
NCT05228652 ·Status: UNKNOWN
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
NCT04806451 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Natural History Study of Patients With Excess Androgen
NCT00250159 ·Status: RECRUITING
-
Fertility and Pregnancy in Patients With Classic Congenital Adrenal Hyperplasia
NCT06153043 ·Status: COMPLETED
-
Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia
NCT01771328 ·Status: UNKNOWN ·Phase: PHASE2
-
Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia
NCT01807364 ·Status: COMPLETED
-
Androgen Reduction in Congenital Adrenal Hyperplasia
NCT03548246 ·Status: WITHDRAWN ·Phase: PHASE2
-
Molecular Basis of the Growth Axis in Short Stature
NCT00453245 ·Status: COMPLETED
-
rhGH Therapy on Hepatic Drug Metabolism
NCT00458991 ·Status: COMPLETED
-
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States
NCT00461240 ·Status: COMPLETED
-
Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
NCT00001521 ·Status: COMPLETED ·Phase: PHASE3
-
Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1
NCT02574910 ·Status: TERMINATED ·Phase: PHASE1
-
Final Height in Patients With CH Diagnosed by the Screening
NCT04734457 ·Status: UNKNOWN
-
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
NCT07187375 ·Status: RECRUITING ·Phase: PHASE2
-
Adrenal Function in GHD Children
NCT03203356 ·Status: COMPLETED
-
Dexamethasone Treatment of Congenital Adrenal Hyperplasia
NCT00621985 ·Status: COMPLETED ·Phase: PHASE2
-
Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients
NCT04860037 ·Status: UNKNOWN
-
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
NCT04045145 ·Status: COMPLETED ·Phase: PHASE2
-
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
NCT00921609 ·Status: COMPLETED
-
C-Type Natriuretic Peptide and Achondroplasia
NCT01541306 ·Status: COMPLETED
-
Pharmacodynamics of CNP During Growth Hormone Treatment
NCT01504802 ·Status: COMPLETED
-
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
NCT01947907 ·Status: COMPLETED ·Phase: PHASE2
-
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
NCT01052623 ·Status: UNKNOWN ·Phase: PHASE4